HIV-associated cervicodorsal lipodystrophy: Etiology and management

被引:14
|
作者
Gold, DR [1 ]
Annino, DJ [1 ]
机构
[1] Tufts Univ, New England Med Ctr, Dept Otolaryngol Head & Neck Surg, Sch Med, Boston, MA 02111 USA
来源
LARYNGOSCOPE | 2005年 / 115卷 / 05期
关键词
HIV-associated lipodystrophy; protease inhibitors; liposuction; cervicodorsal fat pad; buffalo hump;
D O I
10.1097/01.MLG.0000161838.22766.88
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives. To familiarize the otolaryngologist with the evaluation and management of cervicodorsal manifestations of lipodystrophy in patients who have been treated with HIV protease inhibitor medications. In addition, to share the benefits obtainable with ultrasonic tumescent liposuction treatment. Study Design. Retrospective chart review of patients presenting to the senior author with symptomatic hypertrophic cervicodorsal fat pad attributable to HIV infection and HIV protease inhibitor use. Results. Eight patients presented for evaluation of hypertrophic cervicodorsal. fat pads between January 1, 2002 and December 31, 2004. All patients had been on protease inhibitors in the past and had minimal resolution after discontinuing offending agent. Most common presenting problems include disfigurement, limited range of upper extremity and neck motion, neck and back discomfort, and difficulty with sleep including sleep-study-confirmed obstructive sleep apnea. Five of eight patients underwent ultrasonic tumescent liposuction. Three patients had satisfactory improvement of symptoms after the first surgery, whereas the other two required additional operative sessions. No complications of hematoma, seroma, infection, prolonged pain, or re-accumulation of fat pad were encountered. The primary obstacle in the three nonoperative patients was insurance denial on the basis of deemed lack of established necessity. Conclusions: Cervicodorsal lipodystrophy is a well-recognized outcome of prolonged HIV infection and side effect of certain HIV medications. Patients may present with both esthetic and functional issues related to the excess tissue. Although cessation of associated medications may halt further progression, this alone does resolve the symptoms. Ultrasonic tumescent liposuction is shown in this study to be a well-suited modality for reduction of this fibrous adipose tissue. Multiple sessions may be necessary to achieve satisfactory results because of the tenacity of the tissue. It is important for the otolaryngologist to be familiar with the head and neck issues relevant to this disorder and its treatment.
引用
收藏
页码:791 / 795
页数:5
相关论文
共 50 条
  • [1] Clinical management of HIV-associated lipodystrophy
    Pirmohamed, Munir
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2009, 20 (04) : 309 - 314
  • [2] HIV-Associated pruritus - Etiology and management
    Singh, F
    Rudikoff, D
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2003, 4 (03) : 177 - 188
  • [3] Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
    Bedimo, Roger
    [J]. HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2011, 3 : 69 - 79
  • [4] HIV-ASSOCIATED LIPODYSTROPHY AND EXERCISE
    Mutimura, E.
    Stewart, A.
    Crowther, N. J.
    [J]. SOUTH AFRICAN JOURNAL OF PHYSIOTHERAPY, 2006, 62 (02) : 2 - 4
  • [5] The HIV-associated lipodystrophy syndrome
    Mauss, S
    Schmutz, G
    [J]. MEDIZINISCHE KLINIK, 2001, 96 (07) : 391 - 401
  • [6] HIV-associated lipodystrophy syndrome
    Qaqish, RB
    Fisher, E
    Rublein, J
    Wohl, DA
    [J]. PHARMACOTHERAPY, 2000, 20 (01): : 13 - 22
  • [7] HIV-associated lipodystrophy syndrome
    Milinkovic, Ana
    [J]. COLLEGIUM ANTROPOLOGICUM, 2006, 30 : 59 - 62
  • [8] HIV-associated lipodystrophy syndrome
    Mauss, S
    [J]. AIDS, 2000, 14 : S197 - S207
  • [9] TesamorelinA Review of its Use in the Management of HIV-Associated Lipodystrophy
    Sohita Dhillon
    [J]. Drugs, 2011, 71 : 1071 - 1091
  • [10] Tesamorelin A Review of its Use in the Management of HIV-Associated Lipodystrophy
    Dhillon, Sohita
    [J]. DRUGS, 2011, 71 (08) : 1071 - 1091